Search Results

Are you ready to truly understand how pharmacologists predict whole-body drug response from a single Probability Models   This is practical drug development expertise from Terry’s 40+ years of experience GPCR News.   Elevate your pharmacology expertise. Unlock "Pharmacologic Models" now

This week’s feature goes straight to the foundation: how system-level GPCR thinking  protects discovery Upcoming events:  Adhesion GPCR Workshop; GRC—Transporters, Ion Channels & GPCRs; MPGPCR Joint Satellite ; Research Associate—Biologics Discovery. Terry’s Corner: GPCR Pharmacology Insights That Prevent Real Drug Discovery Failures Discovery collapses GPCR Podcast: Chemical Probes for GPCR Imaging with Dr.

And that’s exactly what carries strong discovery programs into 2026.  sit at the core of drug discovery. Academic innovation moves discovery forward only when assays are validated, distributed, and adopted The strongest discovery programs aren’t built on instrumentation alone—they’re built on interpretation Happy holidays—and here’s to a 2026 of cleaner data and faster discovery. 👉 Become a Dr.

Drug Discovery Summit  is bringing together 80+ senior leaders across GPCR-focused biopharma from April NIS is the kind of partner that understands what GPCR discovery actually requires at the structural level global leader in life science innovation, delivering tools and technologies that bridge the gap between discovery unwavering focus on precision, Revvity empowers scientists to simplify complex workflows, accelerate discovery , and drive breakthroughs in drug development, diagnostics, and disease biology.

This is the kinetic detection problem in multi-target GPCR activity, and it has consequences for how scaffolds are interpreted at early stages of discovery.

Why GPCR Drug Discovery Is More Complex Than It Looks G protein-coupled receptors (GPCRs) have long occupied This conceptual shift carries profound implications for GPCR drug discovery . design and immediate drug discovery  relevance. Emerging Families and Orphan GPCRs: Expanding the Drug Discovery Target Space Family A and B GPCRs — — it is a reorientation of the entire GPCR drug discovery  framework.

Measuring GPCR signaling bias in drug discovery is critical, as it forms a selection criterion for agonism Drug discovery programs that do not consider investigating for signaling bias often fail to fully understand How GPCR Signaling Bias Strengthens Drug Discovery Programs There are four distinct reasons why bias measurements improve drug discovery outcomes. Drug Discovery and Development’ eBook and ‘GPCR Functional Cell-based Assays – Assessing Biased Signaling

Emerging GPCR Therapeutic Targets in CNS Drug Discovery GPCRs have been studied for decades, but there Orphan GPCRs in Neurodegenerative Disorders: Integrating Structural Biology and Drug Discovery Approaches for the success of drug discovery, just as much as choosing the right targets. Their integration into drug discovery neuroscience workflows helps accelerate GPCR target identification Orphan GPCRs in Neurodegenerative Disorders: Integrating Structural Biology and Drug Discovery Approaches

In GPCR drug discovery, a single mistaken assumption can derail an entire program. Why Misreading Antagonism Delays GPCR Drug Discovery If a dose-response curve shifts to the right, you Unlock “Competitive Antagonism” Now Only in Terry’s Corner Why Terry’s Corner For discovery-phase teams hunters Influence over upcoming topics Who it’s for:  drug discovery teams, pharmacologists refining Why now:  GPCR research is accelerating—and the projects that succeed will be those built on clear, accurate

of GPCR research and drug discovery. , drug discovery, and biophysics, ensuring you don't miss crucial networking and learning opportunities Terry's Corner - Unlock the Power of Target Residence Time in Your GPCR Drug Discovery Pipeline Gain , and business moves shaping drug discovery. GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need

Enhancing scientific exploration by concentrating on understanding inhibition to advance GPCR drug discovery This Week’s GPCR Intelligence: Every drug you design will meet an enzyme before it meets its receptor Terry's Corner – How Enzyme Inhibition Shapes Every Discovery Program Every molecule meets an enzyme Mastering inhibition isn’t just about avoiding drug–drug interactions. GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need

Elevate Your GPCR Science with Essential Frameworks for Precision Drug Discovery: An Insight into Advanced , Not Breakdowns In the fast-paced world of GPCR drug discovery, the "go fast" mindset can often lead GPCR-Based Drug Discovery conference is where the future of GPCR therapies will be defined. GPCR scientists, translational pharmacologists, biotech drug discovery teams, and decision-makers who Keywords: GPCR, drug discovery, pharmacology, antagonism, competitive, non-competitive, Terry's Corner

This lecture is a roadmap for understanding why two drugs with similar affinity may behave completely Allosteric Thinking Changes the Game in Drug Discovery For decades, drug discovery pipelines have relied But without understanding how GPCR state changes  influence that affinity—or vice versa—drug discovery Terry’s Pharmacology Corner  delivers trusted, razor-sharp insight to help drug discovery professionals Ask-Me-Anything sessions A growing, curated on-demand library Opportunities to shape future topics Built for discovery-phase

Every September, Boston welcomes the global biotech and drug discovery community. drug discovery. discovery. Axxam Axxam is a leading provider of integrated discovery services, supporting the entire drug discovery important and validated target classes in drug discovery.

Discovery programs rarely fail because a molecule “did nothing.” It was revealed only when the drug encountered the full complexity of the cardiovascular regulatory network Kenakin talked about  the specific allosteric properties orthosteric drugs cannot offer. Why Terry’s Corner Give You The GPCR Pharmacology Insights You Need Terry’s Corner gives discovery scientists It equips pharmacologists, discovery teams, and biotech leaders to see around mechanistic corners, recognize

Watch Episode 175 If your model can’t predict the future of GPCR drug discovery, why build it at all? His lab sits at the crossroads of structure-based modeling, computational chemistry, and drug discovery Carlsson also runs a consulting arm  that advises drug discovery teams on GPCR modeling strategy. For drug discovery executives, the message is clear: predictive modeling can shorten timelines, reduce The next frontier in GPCR drug discovery isn’t more structures—it’s smarter models.

By 2011, she had established her own group within the Drug Discovery Biology theme at Monash Institute Why GPCR Spatial Signaling Is Changing Drug Discovery Today, Michelle leads the Spatial Organization drug discovery and precision targeting. It’s a new language for drug discovery. GPCR Podcast 🔓 Want to go deeper? Join   Dr.

🔹 Elevate your strategy → Building clarity in GPCR drug discovery Even the strongest GPCR programs GPCR University Learner Dr. GPCR Podcast - Surviving Discovery’s Gauntlet Dr. Find your edge:  Dodge the traps that derail real drug discovery careers.   Listen Now – Real Lessons from a GPCR Expert ➤ The future of GPCR isn’t waiting. GPCR Team Read Full Edition ➤

Watch Episode 175 From failed assays to breakthroughs in GPCR modeling , Dr. predictions—a sentiment that highlights the skepticism that still exists around modeling in some corners of drug discovery.   As predictive modeling matures, its role will continue to expand, guiding ligand discovery, informing For early-career researchers, the takeaway is direct: GPCR drug discovery will increasingly depend on

residence time to diffusion-driven pharmacodynamics and the discovery of previously untargetable sites Drugs Change the Game For decades, drug design has treated GPCRs as surface targets. Unlock “Intracellular Drugs” Now Only in Terry’s Corner   Why Terry’s Corner In a world where GPCR science Q&A An expanding on‑demand library of past lessons Influence over upcoming topics Whether you’re in discovery pharmacology and drug discovery.

What GPCR Biologic Drugs Reveal About the Active-State Problem Family B GPCRs are conformationally malleable GPCR biologic drugs, peptides in particular, achieve this through a mechanism worth naming carefully. Family B GPCRs have a rich history of allosteric ligands that produce activation. The orthosteric site at a family B GPCR is not closed to small molecules. biologic drugs inherit, and the trafficking decisions that determine receptor fate inside the cell.

GPCR News delivers a toolkit of practical innovations—from drug design strategies that anticipate physiological Breakthroughs this week: Lilly to build $5B manufacturing facility in Virginia; Novo Nordisk flags drug Terry's Corner – Designing Drugs That Anticipate Physiological Pushback Most GPCR programs don’t fail GPCR , our mission is simple but urgent: Accelerate GPCR biology and drug discovery by connecting scientists GPCR scientists, translational pharmacologists, biotech discovery teams, and decision-makers who need

His work highlights how foundational GPCR science can drive therapeutic innovation. The GPCR Angle Ben sees GPCRs as untapped goldmines for drug discovery. Ready to dive deeper into GPCR drug discovery? Want to push the boundaries of GPCR drug discovery? Start learning with our GPCR University today. _______________ Keyword Cloud: GPCR research community , GPCR drug discovery, mu-opioid receptor, positive allosteric modulators, GPCR training program, GPCR

Why Pipeline Efficiency Starts with Physiology Drug discovery doesn’t happen in a vacuum. Reflexes as Drug Design Partners Not all reflexes are enemies. Some can make a mediocre drug shine. This insight has huge implications for how you select and rank agonists in discovery campaigns. But drug discovery isn’t static — it’s a moving target. discovery experience If you’re serious about derisking your pipeline, this is where you sharpen the

Signaling and Translation Tired of HEK293 cells as a model for drug discovery? in Drug Discovery → Read DiscoverX article A2A Fluorescent Competitive Binding with NanoBRET® → Explore It's a comprehensive reference on GPCR drug discovery project initiation, target selection, ligand characterization Aside from his vast experience in drug development, not to mention his extensive publication record, GPCR Course Attendee About Dr. GPCR Dr.

GPCRs are one of the most important families of therapeutic targets in the pharmaceutical industry Approximately one-third of the drugs currently in clinical use are GPCR ligands. The C5a anaphylatoxin chemotactic receptor 1, also known as CD88, is part of the rhodopsin family of GPCRs Trends in GPCR Drug Discovery: New Agents, Targets and Indications. Nature Reviews Drug Discovery 2017 , 16 (12), 829–842. https://doi.org/10.1038/nrd.2017.178 . (2) Dumitru

Welcome back GPCR fans, If your drug discovery strategy still relies on static GPCR models, you’re already discovery and collaboration intersect. Sharpen your discovery decisions ➤ GPCR Signal Transduction Call for Papers: Define What Comes Next Volume On Target: Where the Next Decade of GPCR Drugs Begins If you’re not attending the GPCR-focused sessions GPCR scientists, translational pharmacologists, biotech drug discovery teams, and decision-makers who

Watch Episode 167 Today’s GPCR scientists don’t want to study one interaction, they want to model the protein interactions  (e.g., 14-3-3) Heterodimerization Endogenous vs. overexpressed systems Orphan GPCR scientists are already expanding this work, bringing in computational layers  like AlphaFold to model GPCR-RAMP Listen to the complete episode to learn more. _________________ Keyword Cloud : GPCR scientist network , GPCR online course , GPCR data platform , multiplex assays , GPCR drug discovery

Drugs like Ozempic will change the world GPCR Events, Meetings, and Webinars November 5 - 7, 2024 | 16th Forum Conference November 26 - 28, 2024 | GPCRs-Targeted Drug Discovery Summit Europe NEW December Drug Discovery NEW February 15 - 19, 2025 | BPS 2025 NEW February 16 - 21, 2025 | Harnessing the Power of Advanced Multimodal Approaches to GPCR Drug Discovery NEW March 12 - 14, 2025 | NextGen Biomed 2025 Discovery Chemistry NEW   April 24 - 27, 2025 | American Physiology Summit 2025 NEW April 25 - 30, 2025

Welcome GPCR Fans,   In GPCR-targeted drug discovery, precision isn’t optional—it’s a requirement. GPCR Premium Members this week gain curated, early access to: Industry insights : GPCRs and mRNA in drug Upcoming events : Lab-in-the-Loop AI-powered hit discovery (July 29); 5th Transatlantic GPCR Symposium At this international meeting, leaders shared next-gen strategies shaping modern drug discovery: Prof Scientists, drug discovery teams, and pharmacologists who need curated, career-relevant updates.